

In Memory of Natale Cascinelli

**Melanoma Independent board**  
**THIRD MELANOMA MIB CONFERENCE**  
**INNOVATION AND SUSTAINABILITY**

Rome - November 9<sup>th</sup> 2015



**MEETING CHAIRMAN**

**Alessandro Testori**  
Istituto Europeo di Oncologia, Milano

**MEETING BOARD**

**Paola Queirolo**  
Ospedale San Martino Genova  
**Nicola Mozzillo**  
Istituto Tumori di Napoli  
**Francesco de Lorenzo**  
President European cancer patients coalition (ECPC)  
**Carlo Riccardo Rossi**  
Istituto oncologico Veneto Padova



Cover photograph by Diliff, edited by Vassil. Source Wikimedia Commons



## MEETING CHAIRMAN

**Alessandro Testori** – Istituto Europeo di Oncologia, Milano

## MEETING BOARD

**Paola Queirolo** – Ospedale San Martino Genova

**Nicola Mozzillo** – Istituto Tumori di Napoli

**Francesco de Lorenzo** – President European cancer patients coalition (ECPC)

**Carlo Riccardo Rossi** – Istituto oncologico Veneto Padova



Communication and Organizing Secretary:

**Dea Eventi Srl**

Dott.ssa Moira Boccia

Piazza Cavalotti, 2 - 00040 Castel Gandolfo (RM)

Tel 06.9360565 - Fax 06.93590149

[ladeaeventi@gmail.com](mailto:ladeaeventi@gmail.com)


[www.mib-roma.com](http://www.mib-roma.com)






## SHERATON 2


### LOWER FLOOR / PIANO INFERIORE



### GROUND FLOOR / PIANO TERRA



### FOURTH FLOOR QUARTO PIANO




## Sheraton 2 Parco de' Medici

Viale Salvatore Rebecchini, 39 - 00148 Roma, Italia

T +39 06 65287105 F +39 06 65287060



## SALONE BONCOMPAGNI







## CONTENT

WELCOME MESSAGGE	8
AGENDA - Monday, November 9 <sup>th</sup>	11
FINAL PROGRAM AT A GLANCE	16
FACULTY LIST	20
SPECIFIC ORGANIZATIONAL ASPECTS	23
SPONSORS	24



## WELCOME MESSAGE

### MELANOMA INDEPENDENT BOARD

### THIRD MELANOMA MIB CONFERENCE - NOVEMBER, 9<sup>th</sup> 2015 INNOVATION AND SUSTAINABILITY

**A**fter the success of the previous two meetings, the third edition of the Melanoma Independent Board will discuss three main aspects between the melanoma issues which are actual and under new and continuous development. Firstly the concept of innovation of the various proposals of cure of this disease, of how the new single drugs and integrated therapeutic approaches available may in future develop in combination modalities and how we may improve the ability in selecting the best treatment proposals to obtain the highest chances to cure the specific disease entity of a single melanoma patient; consequently, together with the requisite of innovation, the concept of sustainability will focus on organizational aspects with specific attention to the regulatory pathways, the budget applications, the interaction with payers and the point of view of patients not only in the situation of requiring the best available treatment when discovered, but also in terms of managing their lives once cured from a melanoma. Second topic will be the preparation of the national diagnostic and therapeutic pathways to be proposed to our melanoma patients; this project will be characterized by inviting a selected network of melanoma experts in the different fields and involving representatives from the most important scientific societies directly or indirectly dedicated to diagnosis and cure of melanoma patients. The third topic will be dedicated to the newborn Associazione Italiana Malati di Melanoma (AIMAME) that will organize the first general assembly and plan the priority activities for next year.

#### Innovation

The vast majority of research is conducted by pharma and from a pipeline of thousands of drugs, only few reach the market: this is a crucial aspect in the definition of the difficulty from one side to develop new drugs and explains why this kind of research is in the hands of big companies, while from the other side justifies only in part the increase in prices shown during the last 10 years by new drugs. The total pharmacological expenditure for oncological drugs is anyway a real minority of the global balance of sanitary costs in Italy, where a large amount of spending review can be obtained by rationalizing several inefficient costs like those linked to the excessive number of little hospitals distributed in the national territory and the unexplainable difference of costs of similar devices in different Italian Regions.

Molecular medicine is developing a concept of individualizing the best treatment to be offered to cure the cancer of a single person: it is more than clear that a single drug will not be effective on



all patients affected by a specific disease and the most important task will be the selection and the combination of the drugs to be offered to cure a single patient. In-fact it is becoming more and more clear that the molecular pathways involved in the development and progression of cancer cannot be controlled by a single drug, so the association of different compounds will be a strategic task for the next 10 years of cancer research. This aspect brings the discussion to a very delicate but fundamental aspect which is the necessity that different companies will have to play a common job and activate strategies of cooperation within specific collaborative clinical trials.

Immunology and molecular medicine will represent the future of cancer cure when we shall be able to predict the response and we shall make the investment behind a cure proposal really beneficial, making the treatment proposal to a patient unavoidable: if you are proposing a cure to a cancer patient with a high probability of success, no price limitations will ever be present, firstly because you select the patient to whom a certain therapy is most probable to be effective, secondly because the selection of the patients will limit the number of patients to whom a certain therapy will be offered. Targets of immune response and pharmacological interaction pathways of molecular medicine drugs are the milestones of cancer cure and require all our efforts to be efficiently discussed and finalized.

## Sustainability

The organizational aspects are requiring a new methodology concerning the level of discussion and the rational to guide the decision making processes: new effective treatments are coming available to melanoma patients and we all agree that all new effective therapies should be offered to patients but on the opposite site the NHS budget has to be sustainable as it is not unlimited. This brings the discussion to a setting where different figures should be involved starting from medical experts, pharm company representatives, economists, regulatory agency representatives patients association representatives and media and communication experts; such a panel could be the best scenario to obtain an agreement on the selection of the targets of new therapies, but also on the identification of the characteristics of the centers where a certain treatment could be offered to patients with both the goal of efficacy but also efficiency in terms of costs control.

## Discrimination

Patients with melanoma have a 85-90% probability to be cured from this disease. Are we sure that this aspect is well considered in a life time project concerning a melanoma patient? In reality there is a discrimination in various environments in which a cured melanoma patient may be involved every day and where instead this individual person is instead excluded as previously affected by a melanoma. What about if a melanoma patient wants to obtain a health insurance or a life insurance or wants to buy a house with a bank loan and he receives a refusal due to his melanoma history? We may cure biologically and clinically a melanoma patient, but our legislation permits to this person to be cured also from the juridical point of view?



## Diagnostic and therapeutical pathways

In the next future we shall not be able to offer everything to every patient, but we must be able to offer the best available therapies to the patients who may benefit from it.

Science and cancer care can no more improve without a discussion which involves different roles, and the target of this meeting will be to create a productive evaluation where strategic and scientific issues should be put together.

An important role has to be dedicated to the validation of diagnostic and therapeutic pathways with the identification of certified regional institutions where both the quality of care and the economical sustainability will be guaranteed. To reach this objective of auditing and survey the discussion needs to identify precise markers of quality through validated methods of cost-benefit evaluation. This approach needs to be proposed by recognized Italian scientific societies (IMI – Intergruppo Italiano Melanoma, AIOM - Associazione Italiana di Oncologia Medica, SICO - Società Italiana di Chirurgia Oncologica, SIAPEC - Società Italiana di Anatomia Patologica e Citologica Diagnostica etc.) and ultimately be approved by national and regional health authorities from whom this activity has been formally devoted.

The topics listed below represent the background of the discussion of this third melanoma independent board meeting, from which new topics will be proposed for future discussions and meetings.



## AGENDA

### Roma November 9<sup>th</sup> 2015

**8.00-9.00      Registration Sheraton Parco de' Medici Building N° 2**

---

**First session 9.00 – 11.10**

**Chair Alessandro Testori, Alessandro Minisini**

- |       |  |
|-------|--|
| 9.00  | The Melanoma Independent Board as a model for integrating clinical research and the society<br><b>Alessandro Testori</b> |
| 9.10  | Welcome messages from Italian Regions representatives of Regione Lombardia <b>Maria Teresa Baldini</b>                   |
| 9.20  | Welcome messages from representatives of Regione Lazio <b>Antonio Aurigemma</b>  |
| 9.30  | MIUR Delegato <b>Michela Corsi</b> , saluti  |
| 9.40  | The role of ISS in supporting Italian clinical research projects<br><b>Enrico Proietti</b>                               |
| 9.55  | Melanoma socio-economic epidemiology<br><b>Saverio Caini</b>   |
| 10.05 | Cancer Center certification program in Germany:<br>strengths and weaknesses<br><b>Claus Garbe</b>                        |
| 10.20 | Innovation and sustainability from the point of view of an economist<br><b>Americo Cicchetti</b>                         |
| 10.35 | “Science and Medical Journalism Responsibilities”<br><b>Maria Emilia Bonaccorso</b>                                      |
| 10.50 | E-cancer medical science: a new way to manage a scientific journal<br><b>Gordon McVie</b>                                |
| 11.00 | AIOM representative: Comments/ Discussion on the developed subjects<br><b>Alessandro Minisini</b>                        |



---

## **Second session 11.20 – 12.05**

**Chair Maria Emilia Bonaccorso e Francesco De Lorenzo**

**Round table with insurance companies**

- 11.20        “How the point of view on insurance companies is moving on oncological patients”  
**Giuseppe Gionta**
- 11.35        “Insurance companies approach on cured oncological patients: can we help these people not to be discriminated?”  
**Elisabetta Iannelli**
- 11.50        FASDAC (Fondo di assistenza sanitaria dei Dirigenti di Aziende Commerciali)  
L’esperienza di un fondo sanitario di categoria nell’approccio a sostegno dei pazienti oncologici.  
**Dott. Marco Lignini**
- 12.05        Discussion

---

## **Third session 12.15 – 13.55**

**The pharmaceutical companies research plans**

- 12.15        “BMS melanoma projects”  
**Maria Almerica Gaudino**
- 12.25        “T-VEC: oncolytic immunotherapy platform for the treatment of melanoma”  
**Emerenziana Marturano**
- 12.35        “LYTIX BIOPHARMA Clinical research plans in melanoma from New company in the melanoma world  
**Andrew Saunders**
- 12.45        “Roche: Innovation in melanoma: from BRAF to multiple targets”  
**Alfonso Gentile**
- 12.55        “FIDIA New Therapeutic approach for non-melanoma skin cancer ”  
**Barbara Bellei**
- 13.05        “Electrochemotherapy: Sustainability of innovation in Medical Device Industrial offer”  
**Claudio Viola**
- 13.15        “MSD Immunoncology: from IFN to anti pd1 and beyond”  
**Maria Sofia Rosati**
- 13.25        “Sustainability of new drugs in a global vision of NHS costs”  
**Massimo Visentin**
- 13.35        Lunch



---

#### **Fourth Session 13.55-14.40**

**Comitato scientifico**

**Coordinatore: Alessandro Testori**

**Presidente: Sara Vigna, AIMAME**

**Membri: Ketty Peris, Pietro Quaglino, Carlo Riccardo Rossi, Mozzillo Nicola,**

**Michele Maio, Paolo Ascierto, Sergio Chimenti, Paola Queirolo**

---

#### **Fifth session 14.40 – 15.40**

**Riunione Associazione Italiana Malati di Melanoma (AIMAME)**

Attività associazione AIMAME, presidente Sara Vigna

---

#### **Sixth session 15.40 –19.00**

**Chairman Alessandro Testori**

**Gruppo di lavoro italiano per la definizione dei percorsi diagnostico-terapeutici  
nel melanoma.**

**Coordinatore Alessandro Testori - alessandro.testori@ieo.it**

**Arearie di interesse specialistico proposte:**

- |   |                     |
|---|---------------------|
| • Ricerca di base                         | Andrea Anichini     |
| • Epidemiologica                          | Saverio Caini       |
| • Dermatologica                           | Tutti i dermatologi |
| • Chirurgica                              | Tutti i chirurghi   |
| • Terapia medica adiuvante                | Oncologi medici     |
| • Terapia medica per malattia metastatica | Oncologi medici     |
| • Anatomia patologica e laboratorio       |                     |
| • Follow up                               |                     |
| • Riabilitazione                          |                     |
| • Diagnostica strumentale                 |                     |
| • Psico oncologica                        |                     |

19.00 Learning Test and ECM Educational Activity Test

19.30 Conclusion  
**Alessandro Testori**



---

## Comitato scientifico P.D.T. Italiani nel Melanoma

Coordinatore: Alessandro Testori

Ignazio Stanganelli, Caterina Longo, Giuseppe Spadola, Carlo Riccardo Rossi, Nicola Mozzillo, Massi Daniela, Saverio Caini, Luigi Mascheroni, Luigi Naldi, Michele Maio, Michele Guida.

Assenti giustificati: Giovanni Pellacani, Massimo Barberis, Paolo Ascierto, Francesco Ferrucci, Fantini Fabrizio, Claudio Clemente, Gerardo Botti, Paola Quierolo.



ADOI (Associazione Dermatologi Ospedalieri Italiani).  
Presidente Antonio Cristaudo, delegato Gian Marco Tomassini



AIDA (Associazione Italiana Dermatologi Ambulatoriale).  
Presidente e delegato Domenico Piccolo



AIDNID (Associazione Italiana Diagnostica Non Invasiva in Dermatologia).  
Presidente e delegato Alessandro Di Stefani



AIFI (Associazione Italiana Fisioterapisti). Presidente Monica Mastrullo



AIMAME (Associazione Italiana Malati Melanoma). Presidente Sara Vigna.



AIMN (Associazione Italiana Medicina Nucleare). Presidente Onelio Geatti,  
delegato e coordinatore Pierluigi Zanco



AIOM (Associazione Italiana Oncologia Medica ).  
Delegato Alessandro Minisini, Virginia Ferraresi



AIRO (Associazione Italiana di Radioterapia Oncologica).  
Presidente Riccardo Maurizi Enrici, delegato Andrea Riccardo Filippi



FAVO e ECPC (Federazione Associazioni di Volontariato in Oncologia e European Cancer Patient Coalition)  
Presidente Francesco De Lorenzo



GIPMe. Coordinatore e delegato Marco Simonacci



IMI (Intergruppo Melanoma Italiano).  
Delegati (tutti i membri del comitato scientifico), Palmieri Giuseppe, Andrea Anichini, Maria Antonietta Pizzichetta

ISL (Italian Society of Lymphoangiology).  
Delegato Dr. Stefano Spinaci



ISPLAD. Presidente e Delegato, prof.ssa Ornella De Pita



NIBIT (Network Italiano per la Bioterapiadei Tumori).  
Delegati Anna Maria di Giacomo



SIAPEC (Società Italiana di Anatomia Patologica e Citologia Diagnostica).  
Delegati Daniela Massi, Stefania Staibano



SICO (Società Italiana di Chirurgia Oncologica).  
Achille Gasparri, delegati Corrado Caracò e Franco de Cian



SICPRE (Società Italiana Chirurgia Plastica Ricostruttiva e Estetica).  
Delegato Maria Giuseppina Onesti



SIC,(Società Italiana Chirurgia).  
Presidente Francesco Corcione, delegato Nicola Solari e Franco Di Filippo



SIBIOC (Società Italiana Biochimica Clinica).  
Presidente Ferruccio Ceriotti, delegato dr. Ettore Capoluongo



SICADS (Società Italiana di Chirurgia Ambulatoriale ).  
Presidente Luigi Conte



SIDCO (Società Italiana di Dermatologia Chirurgica ed Oncologica).  
Delegati Davide Strippoli e Antonio Ascari Raccagni



SIDEMAST. Presidente Giampiero Girolomoni,  
delegati Ketty Peris e Giuseppe Argenziano



SIPPO (Società Italiana di Psico-oncologia).  
Delegato Buda Patrizia



SIICA (Società Italiana di Immonologia Immunologia clinica e allergologia).  
Vicepresidente Santoni Angela



SPIF (sindacato professionale italiano fisioterapisti).  
Presidente Antonio Cartisano



SIFIR (Società Italiana Fisioterapia e Riabilitazione).  
Delagato Fara Maria Antonietta, Tondinelli Maria Elena,  
De Marinis Maria Concetta



## **FINAL PROGRAM AT A GLANCE**

- |       |  |  |
|-------|--|--|
| 9.00  | The Melanoma Independent Board as a model for integrating clinical research and the society<br><b>Alessandro Testori</b> |  |
| 9.10  | Welcome messages from Italian Regions representatives of Regione Lombardia<br><b>Maria Teresa Baldini</b>                |  |
| 9.20  | Welcome messages from representatives of Regione Lazio<br><b>Antonio Aurigemma</b>                                       |  |
| 9.30  | MIUR Delegato Michela Corsi, saluti  |  |
| 9.40  | The role of ISS in supporting Italian clinical research projects<br><b>Enrico Proietti</b>                               |  |
| 9.55  | Melanoma socio-economic epidemiology<br><b>Saverio Caini</b>   |  |
| 10.05 | Cancer Center certification program in Germany: strengths and weaknesses<br><b>Claus Garbe</b>                           |  |
| 10.20 | Innovation and sustainability from the point of view of an economist<br><b>Americo Cicchetti</b>                         |  |
| 10.35 | Science and Medical Journalism Responsibilities<br><b>Maria Emilia Bonaccorso</b>  |  |
| 10.50 | E-cancer medical science: a new way to manage a scientific journal<br><b>Gordon McVie</b>                                |  |
| 11.00 | AIOM representative: Comments/Discussion on the developed subjects<br><b>Alessandro Minisini</b>                         |  |
| 11.20 | How the point of view on insurance companies is moving on oncological patients<br><b>Giuseppe Gionta</b>                 |  |



- 11.35 Insurance companies approach on cured oncological patients: can we help these people not to be discriminated?

**Elisabetta Iannelli**

---

---

---

- 11.50 FASDAC (Fondo di assistenza sanitaria dei Dirigenti di Aziende Commerciali)  
L'esperienza di un fondo sanitario di categoria nell'approccio a sostegno dei pazienti oncologici.

**Dott. Marco Lignini**

---

---

---

---

---

---

---

---

- 12.05 Discussion

---

---

- 12.15 BMS melanoma projects  
**Maria Almerica Gaudino**

---

---

- 12.25 T-VEC: oncolytic immunotherapy platform for the treatment of melanoma  
**Emerenziana Marturano**

---

---

---

- 12.35 LYTIX BIOPHARMA Clinical research plans in melanoma from New company in the melanoma world  
**Andrew Saunders**

---

---

---

---

- 12.45 Roche: Innovation in melanoma:  
from BRAF to multiple targets  
**Alfonso Gentile**

---

---

---

- 12.55 FIDIA New Therapeutic approach for non-melanoma skin cancer  
**Barbara Bellei**

---

---

---

- 13.05 Electrochemotherapy:  
Sustainability of innovation in Medical Device Industrial offer  
**Claudio Viola**

---

---

---

---

- 13.15 MSD Immunoncology: from IFN to anti pd1 and beyond  
**Maria Sofia Rosati**

---

---

---

- 13.25 Sustainability of new drugs in a global vision of NHS costs  
**Massimo Visentin**

---

---

---

- 13.35 Lunch

---

---

- 13.55-14.40  
Comitato scientifico  
Coordinatore: Alessandro Testori  
Presidente: Sara Vigna, AIMAME

---

---

---

---



Menbri: Ketty Peris, Pietro Quaglino,  
Carlo Riccardo Rossi, Mozzillo Nicola,  
Alessandro Testori, Michele Maio, Paolo  
Ascierto, Sergio Chimenti, Paola Queirolo

14.40 – 15.40  
Riunione Associazione Italiana Malati di  
Melanoma (AIMAME).  
Attività associazione AIMAME,  
presidente Sara Vigna

15.40 – 19.00  
Chairman Alessandro Testori  
Gruppo di lavoro italiano per la  
definizione dei percorsi diagnostico-ter-  
apeutici nel melanoma.  
Coordinatore Alessandro Testori  
alessandro.testori@ieo.it  
Aree di interesse specialistico proposte:  
• Ricerca di base  
Andrea Anichini  
• Epidemiologica  
Saverio Caini  
• Dermatologica  
Tutti i dermatologi  
• Chirurgica  
Tutti i chirurghi  
• Terapia medica adiuvante  
Oncologi medici  
• Terapia medica per malattia metastatica  
Oncologi medici  
• Anatomia patologica e laboratorio  
• Follow up  
• Riabilitazione  
• Diagnostica strumentale  
• Psico oncologica

19.00 Learning Test and ECM Educational  
Activity Test

19.30 Conclusion  
**Alessandro Testori**



---

## **Adjourn**

At the end of each session the selected rapporteurs will record a summary of the presentations

## **MEETING CHAIRMAN**

Alessandro Testori

Istituto Europeo di Oncologia, Milano

## **MEETING BOARD**

Nicola Mozzillo

Istituto Tumori di Napoli Pascale

Francesco de Lorenzo

President of the European Cancer Patients Coalition (ECPC)

Carlo Riccardo Rossi

Istituto Oncologico Veneto Padova



## FACULTY LIST

### **Dr. ANDREA ANICHINI**

Delegato IMI (Intergruppo Melanoma Italiano)  
Fondazione IRCCS (Istituto Nazionale dei Tumori)  
Human Tumors Immunobiology Unit  
Dept. of Experimental Oncology and Molecular Medicine

### **Prof. GIUSEPPE ARGENZIANO**

Delegato SIDEMAST (Società Italiana di Dermatologia Medica)  
Clinica Dermatologica della Seconda Università di Napoli

### **Dr. ANTONIO ASCARI RACCAGNI**

Delegato SIDCO (Società Italiana di Dermatologia Chirurgica e Oncologica)

### **Dott.ssa MARIA TERESA BALDINI**

Consigliera Regione Lombardia

### **Dott.ssa MARIA EMILIA BONACCORSO**

Giornalista Agenzia ANSA, Roma

### **Prof. ETTORE CAPOLUONGO**

Delegato SIBIOC (Società Italiana Biochimica Clinica)  
Università Cattolica del Sacro Cuore – Policlinico Gemelli, Roma

### **Dr. CORRADO CARACÒ**

Delegato SICO (Società Italiana di Chirurgia Oncologica)  
Dipartimento Melanoma Istituto Nazionale dei Tumori, Napoli

### **Prof. AMERICO CICCHETTI**

Università Cattolica del Sacro Cuore, Milano

### **Dott.ssa DANIELA MASSI**

Delegata SIAPEC (Società Italiana di Anatomia Patologica e Citologia Diagnostica)  
Facoltà di Medicina e Chirurgia, Università degli Studi di Firenze, Firenze

### **Prof. FRANCO DI FILIPPO**

Delegato SIC (Società Italiana Chirurgia)  
Istituti Fisioterapici Ospedalieri, Regina Elena, Roma

### **Dott.ssa ANNAMARIA DI GIACOMO**

Delegata NIBIT (Network Italiano per la Bioterapia dei Tumori)  
Azienda Ospedaliera Universitaria di Siena

### **Prof.ssa ORNELLA DE PITA**

Delegata ISPLAD (Italian Society of Plastic-regenerative and Oncologic Dermatology)

**Dr. ANDREA RICCARDO FILIPPI**

Delegato AIRO (Associazione Italiana di Radioterapia Oncologica)  
Dipartimento di Oncologia, Università di Torino

**Prof. CLAUS GARBE**

University Hospital Tuebingen, Germany

**Prof. GORDON MCVIE**

Editor Ecancer, Istituto Europeo di Oncologia, Milano

**Dr. ALESSANDRO MINISINI**

Delegato AIOM (Associazione Italiana Oncologia Medica)  
Azienda Ospedaliera Universitaria - Udine

**Prof. NICOLA MOZZILLO**

Vice-direttore scientifico Istituto Nazionale dei Tumori di Napoli, Napoli

**Dott. GIUSEPPE GIUDICE**

Delegato SICPRE (Società Italiana Chirurgia Plastica Ricostruttiva ed Estetica)

**Dott. ssa MARIA GIUSEPPINA ONESTI**

Delegata SICPRE (Società Italiana Chirurgia Plastica Ricostruttiva ed Estetica)  
Chirurgia Plastica Università La Sapienza, Roma

**Prof. GIUSEPPE PALMIERI**

Delegato IMI (Intergruppo Melanoma Italiano)  
Unità di Genetica dei Tumori dell'Istituto di Chimica Biomolecolare di Sassari

**Proff.ssa KETTY PERIS**

Delegata SIDEMAST (Società Italiana di Dermatologia Medica)  
Università Cattolica del Sacro Cuore - Policlinico Gemelli, Roma

**Dr. DOMENICO PICCOLO**

Delegato AIDA (Associazione Italiana Dermatologi Ambulatoriale)  
Chirurgia Dermatologica, Università dell'Aquila

**Dr.ssa MARIA ANTONIETTA PIZZICHETTA**

Delegata IMI (Intergruppo Melanoma Italiano)  
Centro di Riferimento Oncologico di Aviano, Istituto Nazionale Tumori

**Dr. ENRICO PROIETTI**

Istituto Superiore di Sanità, Roma

**Prof. CARLO RICCARDO ROSSI**

Istituto Oncologico Veneto, Padova

**Dr. NICOLA SOLARI**

Delegato SIC (Società Italiana Chirurgia)  
Istituto IRCCS San Martino – IST Genova



**Dr. GIUSEPPE SPADOLA**

Istituto Europeo di Oncologia IEO – Milano

**Prof.ssa STEFANIA STAIBANO**

Delegata SIAPEC (Società Italiana di Anatomia Patologica e Citologia Diagnostica)

Università Federico II di Napoli

**Prof. IGNACIO STANGANELLI**

Università degli Studi di Parma

Istituto Oncologico Romagnolo

**Dr. MARCO SIMONACCI**

Delegato GIPME

**Dr. ALESSANDRO TESTORI**

Istituto Europeo di Oncologia, Milano

**Dr. GIANMARCO TOMMASINI**

Delegato ADOI (Associazione Dermatologi Ospedalieri Italiani)

Università degli Studi di Perugia

**Avv. SARA VIGNA**

Libera Professione

**Dr. PERLUIGI ZANCO**

Delegato AIMN (Associazione Italiana Medicina Nucleare)

Ospedale San Bortolo di Vicenza

**Dr. MICHELE GUIDA**

Istituto Tumori Giovanni Paolo II, Brindisi



## SPECIFIC ORGANIZATIONAL ASPECTS

### **Invited Faculties:**

Each invited speaker is kindly requested to send an abstract of the presentation by October 16th

### **Partecipants:**

Registration fee: € 200,00

### **Abstracts Submission:**

Abstracts will be submitted by October 16th; abstracts should be of maximum 600 words, on 1 (one) A4 Format (inclusive of figures), character used will be Times New Roman, dimension 12.

Accepted abstracts will allow a free registration for one person only; no hotel or travel costs will be covered by the organizers of the event.

Two delegates per session will write a summary per each session; summaries will be published on the-cancermedicalscience (ecancer.org) of the European Institute of Oncology.



## MAIN SPONSOR





## PATROCINI REGIONI E ISTITUZIONI



**Regione Lombardia**



**REGIONE AUTONOMA DE SARDIGNA  
REGIONE AUTONOMA DELLA SARDEGNA**



**REGIONE SICILIANA**



**REGIONE CAMPANIA**




**REGIONE BASILICATA**



**CONSIGLIO REGIONALE**



**CONSIGLIO  
REGIONALE  
DEL LAZIO**



**Regione Umbria**



**REGIONE MOLISE**



*Ministero della Salute*



## PATROCINI ASSOCIAZIONI





Società Italiana di Dermatologia  
(SIDeMaST)



Sindacato Professionale Italiano Fisioterapisti  
e Professioni Area Riabilitativa





Communication and Organizing Secretary:  
**Dea Eventi Srl**

Dott.ssa Moira Boccia  
Piazza Cavalotti,2 - 00040 Castel Gandolfo (RM)  
Tel 06.9360565 - Fax 06.93590149

[ladeaeventi@gmail.com](mailto:ladeaeventi@gmail.com)  
[www.mib-roma.com](http://www.mib-roma.com)

